Hennion & Walsh Asset Management, Inc. Seres Therapeutics, Inc. Transaction History

Hennion & Walsh Asset Management, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 20, 2023	SELL	$4.95 - $6.09 $10,355 - $12,740	-2,092 Reduced 3.31%	61,090 $346,000
Q4 2022 Jan 12, 2023	BUY	$5.09 - $9.05 $40,658 - $72,291	7,988 Added 14.47%	63,182 $354,000
Q3 2022 Nov 14, 2022	SELL	$3.5 - $7.2 $2,677 - $5,508	-765 Reduced 1.37%	55,194 $354,000
Q2 2022 Jul 19, 2022	SELL	$2.7 - $7.62 $2,243 - $6,332	-831 Reduced 1.46%	55,959 $192,000
Q1 2022 Apr 26, 2022	BUY	$6.3 - $8.84 $7,301 - $10,245	1,159 Added 2.08%	56,790 $404,000

Q4 2021 Feb 14, 2022	BUY	$6.02 - $11.43 $20,919 - $39,719	3,475 Added 6.66%	55,631 $463,000
Q3 2021 Nov 12, 2021	BUY	$5.46 - $22.6 $97,488 - $403,523	17,855 Added 52.05%	52,156 $363,000
Q2 2021 Aug 13, 2021	BUY	$18.46 - $24.36 $633,196 - $835,572	34,301 New	34,301 $818,000

100

62.7M

36.9K

476K

Ticker MCRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,072,000
Market Cap $89.3M
Description
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...

Get notified when there are updates to the investment portfolio of Hennion & Walsh Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Hennion & Walsh Asset Management, Inc. with notifications on news.